FAQ — MUSE Cell Questions Answered | MUSE Cells

Question 1

What does MUSE stand for?

Accepted Answer

MUSE stands for Multilineage-differentiating Stress Enduring. The name reflects two defining characteristics: the ability to differentiate into multiple cell types (multilineage), and the capacity to survive extreme cellular stress conditions that would destroy most other cell types.

Question 2

Where are MUSE cells found in the body?

Accepted Answer

MUSE cells are found naturally in adult human connective tissues, including bone marrow, skin dermis, and adipose (fat) tissue. They exist as a small subpopulation within mesenchymal stem cell populations and are present throughout the body without any need for genetic modification or laboratory creation.

Question 3

Who discovered MUSE cells?

Accepted Answer

MUSE cells were discovered in 2010 by Professor Mari Dezawa and her research team at Tohoku University in Sendai, Japan. The discovery emerged from studies into stress-resistant subpopulations of bone marrow stem cells. Prof. Dezawa has continued to lead foundational research into MUSE cell biology and therapeutic applications.

Question 4

Are MUSE cells the same as embryonic stem cells?

Accepted Answer

No. MUSE cells are adult stem cells found in living human tissue — they do not come from embryos. While both cell types are pluripotent (capable of differentiating into many cell types), MUSE cells do not require embryonic sources, do not need genetic reprogramming, and critically, do not form tumors when transplanted — a significant safety distinction from embryonic stem cells.

Question 5

Are MUSE cells the same as iPSCs (induced pluripotent stem cells)?

Accepted Answer

No. iPSCs are created by genetically reprogramming adult cells back to a pluripotent state using introduced transcription factors. MUSE cells are naturally pluripotent — they require no genetic modification. iPSCs carry a risk of tumor formation; MUSE cells have not shown this risk in preclinical or clinical studies to date.

Question 6

How do MUSE cells know where to go in the body?

Accepted Answer

When tissue is damaged, the body releases a signaling molecule called sphingosine-1-phosphate (S1P) into the bloodstream. MUSE cells express receptors for S1P on their surface, which allows them to detect and migrate toward the source of the signal — the site of injury. This homing behavior is autonomous and does not require surgical delivery to the target site.

Question 7

Can MUSE cells be given intravenously?

Accepted Answer

Yes. Because MUSE cells home autonomously to injury sites via S1P signaling, they can be administered intravenously (through a vein) and still reach the damaged tissue. This is a significant practical advantage over therapies that require direct surgical injection into the target organ.

Question 8

What cell types can MUSE cells become?

Accepted Answer

MUSE cells are pluripotent, meaning they can differentiate into cell types from all three embryonic germ layers: ectoderm (e.g. neurons, skin cells), mesoderm (e.g. cardiomyocytes, muscle cells, renal cells), and endoderm (e.g. hepatocytes, pancreatic cells). The specific cell type they become is guided by the local tissue environment at the injury site.

Question 9

Do MUSE cells only help through paracrine signaling?

Accepted Answer

No — this is an important distinction. Many stem cell therapies are thought to work primarily through paracrine effects (releasing growth factors that support surrounding tissue). MUSE cells go further: they physically integrate into the host tissue and differentiate into the needed cell types, replacing lost or damaged cells rather than just supporting them from a distance.

Question 10

Do MUSE cells form tumors?

Accepted Answer

MUSE cells have not been observed to form teratomas (tumors) in preclinical animal studies or in human clinical trials to date. This is a critical safety distinction from embryonic stem cells and iPSCs, which carry a known risk of teratoma formation. The non-tumorigenic nature of MUSE cells is considered one of their most important clinical properties.

Question 11

Can donor MUSE cells be used in a different patient (allogeneic use)?

Accepted Answer

Research suggests MUSE cells exhibit low immunogenicity — meaning they are less likely to trigger a strong immune rejection response than many other cell types. This makes them promising candidates for allogeneic (donor-to-patient) transplantation, potentially without the need for strong immunosuppressive drugs. Clinical trials are ongoing to further characterize this property.

Question 12

Are MUSE cell therapies approved for clinical use?

Accepted Answer

As of 2026, MUSE cell-based therapies are in various stages of clinical development. CL2020, a MUSE cell product developed by Life Science Institute (a subsidiary of Mitsubishi Chemical Group), has completed Phase II and Phase II/III trials in Japan for conditions including ALS, stroke, and acute myocardial infarction. Regulatory approval status varies by country and indication — consult current clinical trial registries for the latest information.

Question 13

What conditions are MUSE cells being studied for?

Accepted Answer

MUSE cell research spans a wide range of conditions, including: ischemic stroke, amyotrophic lateral sclerosis (ALS), spinal cord injury, acute myocardial infarction, heart failure, diabetic nephropathy (kidney disease), liver disease, and perinatal hypoxic-ischemic encephalopathy. Research is ongoing and the list of studied indications continues to expand.

Question 14

Is this site affiliated with Tohoku University or Life Science Institute?

Accepted Answer

No. This is an independent educational resource with no affiliation with Tohoku University, Life Science Institute, Mitsubishi Chemical Group, or any research institution or pharmaceutical company. The content is compiled from publicly available peer-reviewed literature for educational purposes only.

Question 15

Is the information on this site medical advice?

Accepted Answer

No. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. MUSE cell therapies are investigational in most jurisdictions. Always consult a qualified healthcare professional before making any medical decisions.

Question 16

How is the content on this site sourced?

Accepted Answer

Content is based on peer-reviewed publications available through PubMed and other academic databases, as well as registered clinical trial data from ClinicalTrials.gov and equivalent registries. Key papers are cited on the Research & Publications page with DOI links to the original sources.

Frequently asked questions

The Basics

How They Work

Safety & Clinical Use

About This Site